- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | SciBase: Interim report | 178 | PR Newswire | STOCKHOLM, Nov. 7, 2025 /PRNewswire/ --
January 1 - September 30, 2025
The third quarter in figures
Net sales were TSEK 10,339 (8,408), +23%, cleared... ► Artikel lesen | |
| 07.11. | The Board of Directors in SciBase resolves on an offer to repurchase outstanding warrants of series TO 2 and intends to resolve on a rights issue of shares of approximately SEK 83 million | 225 | PR Newswire | STOCKHOLM, Nov. 7, 2025 /PRNewswire/ -- The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved to make a repurchase offer for all 498,534... ► Artikel lesen | |
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 07.11. | SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million | 256 | PR Newswire | STOCKHOLM, Nov. 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that SciBase... ► Artikel lesen | |
| 22.10. | Nomination Committee appointed for SciBase Holding's Annual General Meeting in 2026 | 179 | PR Newswire | STOCKHOLM, Oct. 22, 2025 /PRNewswire/ -- The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2026:
Anders... ► Artikel lesen | |
| 26.09. | SciBase: Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis | 287 | PR Newswire | STOCKHOLM, Sept. 26, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, announced today the publication... ► Artikel lesen | |
| 23.09. | SciBase receives initial order for clinical study from Castle Biosciences | 297 | PR Newswire | STOCKHOLM, Sept. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has... ► Artikel lesen | |
| 10.09. | Main owners strengthen their position in SciBase | 303 | PR Newswire | STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that Ribbskottet... ► Artikel lesen | |
| 28.08. | SciBase: New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense | 296 | PR Newswire | STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces the recent publication... ► Artikel lesen | |
| 19.08. | SciBase: Interim report | 363 | PR Newswire | STOCKHOLM, Aug. 19, 2025 /PRNewswire/ --
January 1 - June 30, 2025
The second quarter in figures
Net sales were TSEK 8,791 (6,641), +32%, cleared for currency effects +40%.The... ► Artikel lesen | |
| 01.08. | SciBase announces outcome in directed share issue | 385 | PR Newswire | STOCKHOLM, Aug. 1, 2025 /PRNewswire/ -- On 16 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's Board of Directors resolved, pursuant to the authorisation... ► Artikel lesen | |
| 09.07. | SciBase Launches Nevisense Pilot at Leading University in Southeast Florida | 266 | PR Newswire | STOCKHOLM, July 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a... ► Artikel lesen | |
| 07.07. | SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense. | 310 | PR Newswire | STOCKHOLM, July 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is pleased to announce... ► Artikel lesen | |
| 30.06. | SciBase announces outcome in directed share issue | 210 | PR Newswire | STOCKHOLM, June 30, 2025 /PRNewswire/ -- On 23 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, pursuant to the... ► Artikel lesen | |
| 23.06. | SciBase resolves on a directed share issue of approximately SEK 11 million | 345 | PR Newswire | STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company... ► Artikel lesen | |
| 17.06. | Bulletin from the annual general meeting in SciBase Holding AB (publ) | 428 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
| 17.06. | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 | 402 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase for diagnostic tests | 1 | Seeking Alpha | ||
| 16.06. | SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million | 460 | PR Newswire | STOCKHOLM, June 16, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, pursuant to the authorisation granted by the annual general... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase to develop atopic dermatitis test | 1 | Investing.com | ||
| 16.06. | Castle Biosciences, Inc.: Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases | 209 | GlobeNewswire (Europe) | FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 83,27 | -3,02 % | Roku Unveils Black Friday And Cyber Monday Deals Starting November 20 | WASHINGTON (dpa-AFX) - Beginning November 20, Roku Inc (ROKU) will be offering significant holiday discounts on all of its TVs, streaming devices, and smart home goods. Customers can now purchase... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,083 | -1,78 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 88,00 | -0,45 % | Boston Scientific Up 7% in a Month: How Should You Play the Stock? | ||
| PAUL HARTMANN | 223,00 | 0,00 % | Januar bis Juni 2025: PAUL HARTMANN behauptet sich in herausforderndem Marktumfeld | Heidenheim (ots) - - Umsatzerlöse steigen auf 1.214,0 Mio. EUR, organisches Umsatzwachstum von 1,6 % - Bereinigtes EBITDA liegt bei 125,8 Mio. EUR, bereinigte EBITDA-Rendite bei 10,4 % - Transformationsprogramm... ► Artikel lesen | |
| SYSMEX | 8,550 | -5,00 % | Sysmex H1 Profit Declines | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sysmex Corporation reported that its first half profit attributable to owners of the
parent was 19.0 billion yen, a decline of 26.9% from prior year. Earnings... ► Artikel lesen | |
| ADDLIFE | 16,550 | +0,30 % | AddLife AB: Interim Report January 1 - September 30, 2025 | Good organic growth and strong earnings development"AddLife's companies performed strongly during the quarter. Organic growth was solid, margin improvement continued, earnings increased significantly... ► Artikel lesen | |
| EMBECTA | 12,400 | -1,59 % | embecta Announces Major New Commitment to Direct Relief on World Diabetes Day | Expanded Partnership Will Increase Access to Diabetes Care for Communities Across the U.S. and Globally SANTA BARBARA, CA / ACCESS Newswire / November 14, 2025 / On World Diabetes Day, embecta Corp.... ► Artikel lesen | |
| ENOVIS | 25,800 | -0,77 % | Enovis auf der UBS Global Healthcare Konferenz: Strategische Weichenstellung im Orthopädie-Sektor | ||
| KANGJI MEDICAL | 1,000 | 0,00 % | XFRA 50J: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKANGJI MED.HLDS... ► Artikel lesen | |
| PULMONX | 1,590 | +21,37 % | Pulmonx outlines $89M-$90M 2025 guidance with renewed focus on execution and cost discipline | ||
| SI-BONE | 14,900 | -0,67 % | SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance | Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the... ► Artikel lesen | |
| KOOTH | 1,410 | -0,70 % | Kooth PLC - Transfer of Treasury Shares & Exercise of Options | ||
| PEIJIA MEDICAL | 0,665 | +7,26 % | Peijia Medical Announces 2025 Interim Results | HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets... ► Artikel lesen | |
| LIFECARE ASA | 0,378 | -11,68 % | Lifecare ASA: Financial calendar | ||
| BACTIGUARD | 1,320 | -4,00 % | Bactiguard Holding AB: Bactiguard Holding AB's interim report third quarter 2025 | Continued profitability and clinical evidence supporting future growth
Third quarter 2025 (July - September)
Total revenue amounted to SEK 48.4 (73.9) million, a decrease of SEK 25.5 million corresponding... ► Artikel lesen |
Das Unternehmen SCIBASE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.